ABSTRACT. A 36-year-old woman is reported with a possible variant of the McCune-Albright syndrome. The triad was incomplete because of the absence of skin pigmentation and since the sexual precocity was not evident. The presence of a pituitary mass and the secretorY dynamics of growth hormone and prolactin were suggestive of a mammosomatotroph cell adenoma. A toxic multinodular goiter was also associated, but unique was the INTRODUCTION The syndrome of McCune-Albright consists of the triad of polyostotic fibrous dysplasia, cafe-au-Iait pigmentation 'of the skin and precocious puberty (1), but association with other endocrinopathies is recognized. Sexual precocity occurs in about one third of all patients with polyostotic fibrous dysplasia and is caused by ovarian cysts periodically producing estrogens independent of gonadotropin control (2). Goiter or hyperthyroidism are the second most frequent endocrine abnormality and result from nodular hyperplasia without signs of autoimmunity (3). Acromegaly is mentioned in 23 patients (4-23) and we add the case of a 36-year-old woman who also presented with a premature menstruation, a transient toxic multinodular goiter and in whom the diagnosis of fibrous dysplasia was not suspected clinically.
INTRODUCTION
The syndrome of McCune-Albright consists of the triad of polyostotic fibrous dysplasia, cafe-au-Iait pigmentation 'of the skin and precocious puberty (1), but association with other endocrinopathies is recognized. Sexual precocity occurs in about one third of all patients with polyostotic fibrous dysplasia and is caused by ovarian cysts periodically producing estrogens independent of gonadotropin control (2). Goiter or hyperthyroidism are the second most frequent endocrine abnormality and result from nodular hyperplasia without signs of autoimmunity (3). Acromegaly is mentioned in 23 patients (4-23) and we add the case of a 36-year-old woman who also presented with a premature menstruation, a transient toxic multinodular goiter and in whom the diagnosis of fibrous dysplasia was not suspected clinically.
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Received November 25, 1989; accepted May 17, 1990. 671 spontaneous normalization of the thyroid function. Unusual was the silent evolution of the polyostotic fibrous dysplasia, which was only fortuitously discovered during magnetic resonance imaging of the pituitary region. Treatment of the acromegaly with the long-acting somatostatin analogue octreotide resulted in an important inhibition of the GH secretion and in a reduction of the volume of the pituitary adenoma.
CASE REPORT
A 36-year-old woman was referred in 1987 with a longstanding goiter. The family history was unremarkable. The patient had one vaginal bleeding at the age of 8 yr, but developed pubertal growth and menarche only 5 yr later. She had an irregular menstrual cycle for some years and amenorrhea since 2 yr. In 1980 she presented a toxic multinodular goiter, demonstrated by elevated thyroid hormone levels, suppressed TSH levels, absent antimicrosomal antibodies and a heterogeneous distribution of radioactivity on a 99m-Tc thyroid scanning. Methimazole was uneventfully stopped after a treatment of 6 months. She never had any bone problem. On physical examination a large multinodular goiter and typical features of acromegaly were present, but no skin lesion nor bone deformity. Sphenoid bone dysplasia was suspected on a magnetic resonance (MR) image of the sellar region and diagnosis of polyostotic fibrous dysplasia was confirmed by conventional radiology and by a 99mTc-labeled MOP bone scintigraphy showing a scattered involvement of the whole skeletal system. After evaluation of the acromegaly a treatment with bromocriptine was started but stopped after six months be-cause of unsatisfactory results. Two months later it was replaced by octreotide (Sandostatin®, Sandoz Ltd, Basle, Switzerland) in increasing doses. Commercial kits were used for measuring serum concentrations of GH and PRL. They were calibrated using the international standards GH 66/217 and PRL 81 1541 (MRC) as reference preparations.
The other hormone measurements were also performed with commercial kits. Serum growth hormone releasing hormone (GHRH) levels were determined by M. Losa and K. von Werder, University of Munich, Germany, using a radioimmunoassay technique after affinity chromatography. Serum for GH and PRL was sampled hourly over 24 h. GH and PRL responses to an 80 p.g iv dose of GHRH were determined. Plasma levels of insulinlike growth factor I (IGF-I) were assayed. Thyroid function was evaluated by measuring the basal serum concentration of free T 3' free T 4 and the TSH response to a 200 p.g iv dose of TRH; GH and PRL determinations were also made during this test. Blood was sampled every h during 8 h for GH and PRL determinations after a 5 mg oral dose of bromocriptine and after a 100 p.g sc dose of octreotide. Gonadal function was assessed by determining basal estradiol, progesterone, LH and FSH and the gonadotropin response to a 100 p.g iv dose of GnRH. An oral glucose tolerance test was carried out with 75 g of glucose to determine the glycemic, insulinemic and GH responses. During the octreotide treatment blood was sampled hourly over a 12-h period every three months and GH, PRL and blood glucose profiles and fasting plasma IGF-I levels were assessed.
RESULTS
GH levels (normal: < 10 p.g/l) remained elevated throughout the day, with the lowest value of 63 p.g/l at 09:00 h and the highest values during sleep with a maximal level of 104 p.g/l at 03:00h. GH values increased from 68 to 151 p.g/l after stimulation with TRH and from 76 to 130 p.g/l after GHRH. GH decreased from 70 to 48 p.g/l after an oral glucose load. GH values decreased from 58 to 13 p.g/l 4 h after bromocriptine and from 66 to 11 p.g/l 3 h after octreotide.
PRL values (normal: < 20 p.g/l) were continuously elevated, the lowest level of 27 p.g/l occurring at 14:00 h, slightly higher levels during sleep and the 672 highest level of 33 p.g/l occurring at 03:00 h. PRL values increased from 29 to 67 p.g/l after stimulation with TRH and from 27 to 33 p.g/l after GHRH. PRL levels decreased from 24 to 4 p.g/l 6 h after bromocriptine and from 32 to 16 p.g/l 4 h after octreotide. IGF-I values were elevated at 5.7 x 10 3 UII (normal : < 2.0). In response to GnRH LH increased from 1.9 to 9.5 lUll and FSH from 2.1 to 5.5 lUll. Estradiol level was low. Serum alpha-subunit levels were normal. Thyroid function was normal with an adequate response of TSH after TRH from 0.9 to 7.6 mUll after 20 min. Antimicrosomal and TSH-receptor antibodies were not detected. Adrenal function was normal. Sampling of the sinus petrosus on both sides performed in basal conditions and after TRH stimulation showed the highest basal and stimulated GH levels in the right sinus petrosus. The peripheral and sinus petrosus GHRH levels (normal: < 20 ng/l) varied between 16 and 20 ngll without any gradient. After 6 months of treatment with 30 mg bromocriptine GH levels still oscillated between 50 and 74 p.g/l, IGF-I levels between 3.9 and 4.6 x 10 3 UII and PRL levels normalized. Treatment with octreotide resulted in better GH suppression without reaching normal values. The lowest dose of octreotide that produced maximal GH suppression appeared to be 3x200 p.g daily, which was equally effective as 3x500 p.g (Fig. 1) . IGF-I values remained elevated irrespective of the dose. PRL levels normalized and the menstual cycle resumed. 
